EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
AIMS: To determine whether the Joint European Societies guidelines on cardiovascular prevention are being followed in everyday clinical practice of secondary prevention and to describe the lifestyle, risk factor and therapeutic management of coronary patients across Europe. METHODS AND RESULTS: EUROASPIRE IV was a cross-sectional study undertaken at 78 centres from 24 European countries. Patients <80 years with coronary disease who had coronary artery bypass graft, percutaneous coronary intervention or an acute coronary syndrome were identified from hospital records and interviewed and examined ≥ 6 months later. A total of 16,426 medical records were reviewed and 7998 patients (24.4% females) interviewed. At interview, 16.0% of patients smoked cigarettes, and 48.6% of those smoking at the time of the event were persistent smokers. Little or no physical activity was reported by 59.9%; 37.6% were obese (BMI ≥ 30 kg/m(2)) and 58.2% centrally obese (waist circumference ≥ 102 cm in men or ≥88 cm in women); 42.7% had blood pressure ≥ 140/90 mmHg (≥140/80 in people with diabetes); 80.5% had low-density lipoprotein cholesterol ≥ 1.8 mmol/l and 26.8% reported having diabetes. Cardioprotective medication was: anti-platelets 93.8%; beta-blockers 82.6%; angiotensin-converting enzyme inhibitors/angiotensin receptor blockers 75.1%; and statins 85.7%. Of the patients 50.7% were advised to participate in a cardiac rehabilitation programme and 81.3% of those advised attended at least one-half of the sessions. CONCLUSION: A large majority of coronary patients do not achieve the guideline standards for secondary prevention with high prevalences of persistent smoking, unhealthy diets, physical inactivity and consequently most patients are overweight or obese with a high prevalence of diabetes. Risk factor control is inadequate despite high reported use of medications and there are large variations in secondary prevention practice between centres. Less than one-half of the coronary patients access cardiac prevention and rehabilitation programmes. All coronary and vascular patients require a modern preventive cardiology programme, appropriately adapted to medical and cultural settings in each country, to achieve healthier lifestyles, better risk factor control and adherence with cardioprotective medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationLaw, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
Taylor, R. S., Brown, A., Ebrahim, S., Jolliffe, J., Noorani, H., Rees, K., Skidmore, B., Stone, J. A., Thompson, D. R., & Oldridge, N. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.01.009 · Cited by 2,239
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Participation Rates in Epidemiologic Studies
Galea, S., & Tracy, M. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.03.013 · Cited by 1,877
Cited by
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citation2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Self-citationWilliams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Self-citationKotseva, K., De Backer, G., De Bacquer, D., Rydén, L., Hoes, A., Grobbee, D., Maggioni, A., Marques-Vidal, P., Jennings, C., Abreu, A., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487318825350 · Cited by 937
Self-citation2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.037 · Cited by 486
De Backer, G., Jankowski, P., Kotseva, K., Mirrakhimov, E., Reiner, Ž., Rydén, L., Tokgözoğlu, L., Wood, D., De Bacquer, D., De Backer, G., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.03.014 · Cited by 383
Self-citationAaby, A., Friis, K., Christensen, B., Rowlands, G., & Maindal, H. T. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317729538 · Cited by 359
Frederix, I., Caiani, E. G., Dendale, P., Anker, S., Bax, J., Böhm, A., Cowie, M., Crawford, J., de Groot, N., Dilaveris, P., et al. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319832394 · Cited by 323
“Despite the availability of effective guideline-based treatment options, long-term benefits of these treatments are often disappointing due to low uptake and/or non-adherence.(3,4) As an example, the ESC guidelines recommend secondary prevention programmes, i.”
BackgroundRisk Factors for Nonadherence to Antihypertensive Treatment
Gupta, P., Patel, P., Štrauch, B., Lai, F. Y., Akbarov, A., Marešová, V., White, C. M. J., Petrák, O., Gulsin, G. S., Patel, V., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.116.08729 · Cited by 256
Gupta, P., Patel, P., Štrauch, B., Lai, F. Y., Akbarov, A., Gulsin, G. S., Beech, A., Marešová, V., Topham, P. S., Stanley, A., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09631 · Cited by 194
Albus, C., Waller, C., Fritzsche, K., Gunold, H., Haass, M., Hamann, B., Kindermann, I., Köllner, V., Leithäuser, B., Marx, N., et al. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01488-w · Cited by 178
F. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
Rao, A., Zecchin, R., Newton, P., Phillips, J., DiGiacomo, M., Denniss, A., & Hickman, L. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871716 · Cited by 146
On behalf of the EUROASPIRE Investigators, Gyberg, V., De Bacquer, D., De Backer, G., Jennings, C., Kotseva, K., Mellbin, L., Schnell, O., Tuomilehto, J., Wood, D., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0296-y · Cited by 140
Self-citationKandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Ž., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/8732360 · Cited by 136
“Statins, which are 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are broadly used as lipid-lowering drugs in patients with cardiovascular diseases (CVDs) [1, 2].”
BackgroundSelf-citationPedersen, L. R., Olsen, R. H., Anholm, C., Astrup, A., Eugen-Olsen, J., Fenger, M., Simonsen, L., Walzem, R. L., Haugaard, S. B., & Prescott, E. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0934-x · Cited by 98
How to Screen for Non-Adherence to Antihypertensive Therapy
Gupta, P., Patel, P., Horne, R., Buchanan, H., Williams, B., & Tomaszewski, M. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0697-7 · Cited by 84
Hobbs, F. R., Banach, M., Mikhailidis, D. P., Malhotra, A., & Capewell, S. (2016) · BMC Medicine · doi:10.1186/s12916-016-0550-5 · Cited by 76
Ferrannini, G., De Bacquer, D., De Backer, G., Kotseva, K., Mellbin, L., Wood, D., Rydén, L., collaborators, E. V., Gale, C. P., Beleslin, B., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2165 · Cited by 75
Self-citationBrørs, G., Pettersen, T. R., Hansen, T. B., Fridlund, B., Hølvold, L. B., Lund, H., & Norekvål, T. M. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4106-1 · Cited by 67
EUROASPIRE IV & V Investigators, Ferrannini, G., De Bacquer, D., Vynckier, P., De Backer, G., Gyberg, V., Kotseva, K., Mellbin, L., Norhammar, A., Tuomilehto, J., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01233-6 · Cited by 54
Self-citationLaufs, U., Karmann, B., & Pittrow, D. (2016) · Clinical Research in Cardiology · doi:10.1007/s00392-016-0991-z · Cited by 59
World Heart Federation Cholesterol Roadmap
Murphy, A., Faria-Neto, J. R., Al-Rasadi, K., Blom, D., Catapano, A., Cuevas, A., Lopez-Jimenez, F., Perel, P., Santos, R., Sniderman, A., et al. (2017) · Global Heart · doi:10.1016/j.gheart.2017.03.002 · Cited by 43
Self-citationBreaking Barriers: Mobile Health Interventions for Cardiovascular Disease
Klimis, H., Thakkar, J., & Chow, C. K. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.012 · Cited by 40
Karataş, T., & Polat, Ü. (2021) · Patient Education and Counseling · doi:10.1016/j.pec.2020.10.003 · Cited by 32
Murphy, C., Bennett, K., Fahey, T., Shelley, E., Graham, I., & Kenny, R. A. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008017 · Cited by 25
More Versus Less Blood Pressure Lowering: An Update
Atkins, E. R., & Rodgers, A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.08.007 · Cited by 12
Metadata
- Authors
- Kotseva, K., Wood, D., De Bacquer, D., De Backer, G., Rydén, L., Jennings, C., Gyberg, V., Amouyel, P., Bruthans, J., Castro Conde, A., Cífková, R., Deckers, J. W., De Sutter, J., Dilic, M., Dolzhenko, M., Erglis, A., Fras, Z., Gaita, D., Gotcheva, N., Goudevenos, J., Heuschmann, P., Laucevicius, A., Lehto, S., Lovic, D., Miličić, D., Moore, D., Nicolaides, E., Oganov, R., Pajak, A., Pogosova, N., Reiner, Z., Stagmo, M., Störk, S., Tokgözoğlu, L., Vulic, D., & on behalf of the EUROASPIRE Investigators
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-02-16
- Volume
- 23
- Issue
- 6
- Pages
- 636-648
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2134453898
- Cited by
- 1,006
- References
- 51
- FWCI
- 95.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.